key: cord-1014549-y59k3aso authors: Son, Ho Anh; Hang, Dinh Thi Thu; Thuan, Nghiem Duc; Quyen, Le Thi Bao; Thuong, Luong Thi Hoai; Nga, Vu Thi; Quang, Le Bach; Hung, Trinh Thanh; Son, Nguyen Thai; Linh, Nguyen Tung; Nam, Le Van; Van Ba, Nguyen; Tien, Tran Viet; Quyet, Do; Van Luong, Hoang; Su, Hoang Xuan title: A Simple Method for Detection of a Novel Coronavirus (SARS‐CoV‐2) using One‐step RT‐PCR followed by Restriction Fragment Length Polymorphism date: 2020-06-12 journal: J Med Virol DOI: 10.1002/jmv.26171 sha: 8845821c04369171cf83e578e9f84949afc9c4db doc_id: 1014549 cord_uid: y59k3aso BACKGROUND: A novel coronavirus associated with acute respiratory disease (named SARS‐CoV‐2) is recently identified in Wuhan city, China, spread rapidly worldwide. An early identification of this novel coronavirus by molecular tools is critical for surveillance and control of the epidemic outbreak. OBJECTIVES: We aimed to establish a simple method for detection of SARS‐CoV‐2 in differentiating with SARS‐CoV. STUDY DESIGN: Primers of our in‐house RT‐PCR assays were designed to target conserved regions of the RdRP gene and E gene, selected restriction enzymes EcoRI, Tsp45I and AluI to distinguish between SARS‐CoV‐2 and SARS‐CoV. RESULTS AND DISCUSSIONS: In this report, a 396 bp fragment of the RdRp gene and 345 bp fragment of the E gene were amplified by one‐step RT‐PCR. Enzyme Tsp45I cuts the RdRP amplified product of SARS‐CoV‐2 generating 3 fragments of 45, 154 and 197 bp, but it did not cut the amplicon of SARS‐CoV. In contrast, the amplified product of SARS‐CoV was digested with EcoRI producing 2 fragments of 76 and 320 bp, whereas, the amplicon of SARS‐CoV‐2 was undigested by Tsp45I help to distinguish clearly SARS‐CoV‐2 from SARS‐CoV on gel electrophoresis. In addition, AluI cut the amplicon of the E gene of SARS‐CoV‐2 generating 2 fragments of 248 and 97 bp without cutting to SARS‐CoV. Accuracy of assay was confirmed by sequencing and phylogenetic analysis. When evaluated on clinical samples showed a high sensitivity of 95%, specificity of our assay was 100% and clinical performance for detection of SARS‐CoV‐2 in comparison with other reference assays. In conclusion, the present study, we successfully developed a simple method for molecular detection of SARS‐CoV‐2 in differentiating with SARS‐CoV. This article is protected by copyright. All rights reserved. An outbreak of an acute respiratory disease caused by a 2019 novel coronavirus (2019-nCoV) in Wuhan, a central city of Hubei, China has spread rapidly worldwide and posed a global challenge for public health 1 . So far, there were more than 78.000 people infected with 2019-nCoV confirmed and 2445 death have been reported in 28 countries and territory regions 2 . The transmission from human to human through close contact confirmed among infected cases, but secondary spread has been limited in returning travelers from epidemic region 3 , 4 . Based on complete genome sequence and phylogenetic analysis indicated that this novel coronavirus is associated with human severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), 5 and recently, it was designated as SARS-CoV-2 6 . It shares 79% identity with SARS-CoV and might also use ACE2 as a cell receptor 7 . Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 is an enveloped RNA coronavirus belonging to betacoronavirus subfamily, sarbecovirus subgenus of This article is protected by copyright. All rights reserved. Coronaviridae family, but it appears the less pathogenic and more contagious and the mortality rate of SARS-CoV-2 is lower than that of MERS-CoV (~35%) and SARS-CoV (~10%) 8 . To response at the potential risk of pandemic outbreak spread worldwide, the WHO declared the outbreak of SARS-CoV-2 in China as "Public health emergency of international concern" and called substantial global response for the control of this epidemic. There has been no available vaccine or specifically antiviral drugs for prevention and treatment of Covid-19 5 . An important point of SARS-CoV-2 infection has a long period of incubation up to 14 days, longer than SARS-CoV which may lead to a high rate of asymtomatic cases and it may also facilitae rapid spread of SARS-CoV-2 around the world 9 . Therefore, an early detection of suspected cases plays a critical role for management, surveillance, and control of this deadly epidemic. WHO and CDC recommended the use of real-time RT-PCR assay for confirmatory detection of SARS-CoV-2 in clinical virology laboratory 10 , 11 . However, commercial real-time RT-PCR kits approved by FDA are not available, whereas isolation and viral culture method must be performed under Biosafety level 3 (BSL-3) facility and RNA -based metagenomic next generation sequencing analysis require modern equipment and technical expertise 12 , 13 , 14 . Therefore, a simple, rapid assay with affordable cost in resource-limiting countries is very essential for early detection of suspected cases on inactivated clinical specimens. This study aims to establish a simple method for detection of SARS-CoV-2 using one-step RT-PCR This article is protected by copyright. All rights reserved. followed by restriction fragment length polymorphism for detection of SARS-CoV-2 in Vietnam. Transcribed RNAs were estimated as 4.23 x 10 12 copies/μl for the E gene and 2.7 x 10 12 copies/μl for the RdRp gene. Then, a serial dilution from 10 0 -10 6 copies/μl of purified viral RNA transcripts were used as positive controls for development and validation of our molecular assays to identify SARS-CoV-2. One-step RT-PCR reaction was optimized in a total volume of 30 μl using One- (95% CI) for sensitivity, specificity. Cohen's kappa values were calculated for evaluating overall agreement and comparing assays. P values < 0.05 were considered as statistically significant. In our method, we designed primer sets to amplify the RdRp gene fragment of Results as shown in Figure 4 and there was no nonspecific amplification was detected with primer sets used in this study. The restriction enzymes are selected with the aid of Nebcutter V2.0 (www.tools.neb.com/NEBcutter2), which are able to distinguish between SARS-CoV-2 and SARS-CoV by restriction fragments. RFLP strategy for RdRP product was illustrated as This article is protected by copyright. All rights reserved. Furthermore, for more reliable identification of SARS-CoV-2, the amplified product of the E gene for coronavirus was cut by AluI. Theoretically, there was only restriction site on the E gene of SARS-CoV-2 recognized by AluI producing 2 fragments of 248 and 97 bp. The E gene amplicons of SARS-CoV, on the contrary, was not cut by AluI (Figure 3 and 7) . This is a challenge problem for selection of highly conserved regions to design primers and probes of molecular diagnostic assays of SARS-CoV-2. Recently, molecular assays based on real-time RT-PCR were developed by authors, but they were optimized on synthetic transcribed RNAs of SARS-CoV-2 15 , 19 . Therefore, it needs to be validated on sample panels of RNA extracted from inactivated cell culture supernatant of SARS-CoV-2 or clinical specimens collected of confirmed patients before launching for clinical virology laboratories. In this study, based on sequences analysis retrieved from GenBank, GISAID (Table 1) Additionally, it is a specific and definitive discriminatory test for SARS-CoV-2 and SARS-CoV, providing a useful molecular tool for screening of suspected cases. When assessed on clinical samples in comparison with other reference assays demonstrated a high sensitivity of 95% and clinical diagnostic performance for detection of SARS-CoV-2 with high kappa values observed, confirming a high concordance with reference assays (table 2) . Interestingly, the specificity of assay was 100 % and no false positive results observed with other coronaviruses tested in this study (figure 5). To our knowledge, this is the first report presented an in-house RT-PCR allowed for differential detection of SARS-CoV-2 with This article is protected by copyright. All rights reserved. CoV-2 assays, respectively. This could be explained that this specimen had a low concentration of SARS-CoV-2 and it could be below the LOD of our assay. Recently, there was a publication introduced a RT-PCR assay for detection of coronaviruses from four genera with the LOD ranged from 4 to 4 × 10 2 copies/reaction, depending on the CoV species tested, This assay detected all previously known CoVs, including SARS-CoV-2, but it could not distinguish SARS-CoV with SARS-CoV-2 20 . In conclusion, the present study, we successfully developed a simple and effective-cost method for molecular detection of SARS-CoV-2 in differentiating with SARS-CoV. This helps to effectively control of COVID-19 in resourcechallenged settings. A Novel Coronavirus from Patients with Pneumonia in China Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam Accepted Article transmission: a study of a family cluster Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern A distinct name is needed for the new coronavirus Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Emerging coronaviruses: genome structure, replication, and pathogenesis Does SARS-CoV-2 has a longer incubation period than SARS and MERS? Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Biosaf Health Clinical Specimens: Novel Coronavirus Department of Health Science T and E National Health Commission of People's Republic of China This article is protected by copyright. All rights reserved RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR The European Virus Archive goes global: A growing resource for research Return of the Coronavirus: 2019-nCoV Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia A RT-PCR assay for the detection of coronaviruses from four genera Human Coronavirus HKU1 Genbank EPI_ISL_402119 SARS-CoV-2 GISAID EPI_ISL_402120 SARS-CoV-2 GISAID EPI_ISL_402125 SARS-CoV-2 GISAID EPI_ISL_402128 SARS-CoV-2 GISAID EPI_ISL_402132 SARS-CoV-2 GISAID EPI_ISL_403932 SARS-CoV-2 GISAID EPI_ISL_403962 SARS-CoV-2 GISAID This article is protected by copyright We thank Dr. Van Dinh Trang in the National Hospital of Tropical Diseases for excellent laboratory assistance with this study. We also thank Dr. Mark Bertram from Altona Diagnostics for providing the reagents used in this study. This work was supported by the grant from the Ministry of Science and Technology of This article is protected by copyright. All rights reserved. Vietnam (No. grant: 29/20-ĐTĐL.CN-CNN). This publication was supported by the European Virus Archive goes Global (EVAg) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 653316. The authors have no conflicts of interest to disclose